POISE - 2
Perioperative Ischemic Evaluation-2 Trial
To determine the impact of clonidine versus placebo and ASA versus placebo on the 30-day risk of all-cause mortality or nonfatal myocardial infarction in patients with, or at risk of, atherosclerotic disease who are undergoing noncardiac surgery. Patients in the POISE-2 trial will be randomly assigned to one of four groups: ASA and Clonidine together, ASA and Clonidine placebo, ASA placebo and Clonidine, or a ASA placebo and Clonidine placebo. Research personnel will follow patients at 30 days post-randomization and 1 year post-randomization.
Randomized, double-blind, placebo control, factorial assignment, safety/efficacy study.
Composite of all-cause mortality and nonfatal MI at 30 days after randomization
Number of Patients
Number of Sites
Number of Countries
Susan Chrolavicius, Shirley Pettit
- Devereaux et al. Aspirin in Patients Undergoing Noncardiac Surgery. New England Journal of Medicine 2014 Apr 17;370(16):1494-503.
- Devereaux et al. Clonidine in Patients Undergoing Noncardiac Surgery. New England Journal of Medicine 2014 Apr 17;370(16):1504-13.
- Devereaux et al. Rationale and design of the PeriOperative ISchemic Evaluation-2 (POISE-2) Trial: An international 2 X 2 factorial randomized controlled trial of acetyl-salicylic acid versus placebo and clonidine versus placebo in patients undergoing noncardiac surgery. American Heart Journal 2014 Jun;167(6):804-809.e4.
- Garg et al. Aspirin and clonidine in non-cardiac surgery: acute kidney injury substudy protocol of the Perioperative Ischaemic Evaluation (POISE) 2 randomised controlled trial. British Medical Journal Open. 2014 Feb 25;4(2):e004886.